Latest Financial Health News

Pure Hydrogen reports a second consecutive quarter of positive cash flow, expands its international hydrogen vehicle footprint, and secures a 15-year gas project permit in Queensland.

Savannah Goldfields reported a $4.06 million cash outflow in Q2 2025 but is advancing plans to restart gold production and secure additional funding.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

FirstWave Cloud Technology reports a slight revenue decline in Q4 FY25, offsets challenges with strategic restructuring and a new AWS marketplace partnership.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

Group 6 Metals Limited has reported record quarterly tungsten production and sales, completed a major recapitalisation reducing debt, and is transitioning from open cut to underground mining at its Dolphin Tungsten Mine.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

FlexiRoam Limited has achieved profitability in Q4 FY25, marking a significant turnaround with a positive EBITDA and net profit. Founder Jefrey Ong is appointed permanent CEO to steer the company’s next growth phase.

Vection Technologies capped FY25 with its highest monthly order intake ever, driven by defence and AI/XR contracts, while posting positive pro-forma cash flow despite payment timing issues.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.